Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma
- PMID: 16729333
- DOI: 10.1002/hep.21203
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma
Abstract
Human telomerase reverse transcriptase, hTERT, has been identified as the catalytic enzyme required for telomere elongation. hTERT is expressed in most tumor cells but seldom expressed in most human adult cells. It has been reported that 80% to 90% of hepatocellular carcinomas (HCCs) express hTERT, making the enzyme a potential target in immunotherapy for HCC. In the current study, we identified hTERT-derived, HLA-A*2402-restricted cytotoxic T cell (CTL) epitopes and analyzed hTERT-specific CTL responses in patients with HCC. Peptides containing the epitopes showed high affinity to bind HLA-A*2402 in a major histocompatibility complex binding assay and were able to induce hTERT-specific CTLs in both hTERT cDNA-immunized HLA-A*2402/Kb transgenic mice and patients with HCC. The CTLs were able to kill hepatoma cell lines depending on hTERT expression levels in an HLA-A*2402-restricted manner and induced irrespective of hepatitis viral infection. The number of single hTERT epitope-specific T cells detected by ELISPOT assay was 10 to 100 specific cells per 3 x 10(5) PBMCs, and positive T cell responses were observed in 6.9% to 12.5% of HCC patients. hTERT-specific T cell responses were observed even in the patients with early stages of HCC. The frequency of hTERT/tetramer+ CD8+ T cells in the tumor tissue of patients with HCC was quite high, and they were functional. In conclusion, these results suggest that hTERT is an attractive target for T-cell-based immunotherapy for HCC, and the identified hTERT epitopes may be valuable both for immunotherapy and for analyzing host immune responses to HCC.
Similar articles
-
Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.Clin Cancer Res. 2006 May 15;12(10):3158-67. doi: 10.1158/1078-0432.CCR-05-2647. Clin Cancer Res. 2006. PMID: 16707616
-
Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.Oncol Rep. 2007 Jul;18(1):279-85. Oncol Rep. 2007. PMID: 17549380
-
Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.Clin Cancer Res. 2001 Nov;7(11):3343-8. Clin Cancer Res. 2001. PMID: 11705846
-
[Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].Ai Zheng. 2003 Aug;22(8):893-5. Ai Zheng. 2003. PMID: 12917043 Review. Chinese.
-
The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.Clin Ter. 2004 May;155(5):187-99. Clin Ter. 2004. PMID: 15344567 Review.
Cited by
-
Co-culture of primary human tumor hepatocytes from patients with hepatocellular carcinoma with autologous peripheral blood mononuclear cells: study of their in vitro immunological interactions.BMC Gastroenterol. 2013 Jan 18;13:17. doi: 10.1186/1471-230X-13-17. BMC Gastroenterol. 2013. PMID: 23331458 Free PMC article.
-
Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting.Mol Biotechnol. 2010 May;45(1):71-81. doi: 10.1007/s12033-010-9244-y. Mol Biotechnol. 2010. PMID: 20108058
-
Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Cancer Immunol Immunother. 2016 Jun;65(6):715-25. doi: 10.1007/s00262-016-1837-2. Epub 2016 Apr 15. Cancer Immunol Immunother. 2016. PMID: 27083166 Free PMC article.
-
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.Front Immunol. 2021 Oct 4;12:765101. doi: 10.3389/fimmu.2021.765101. eCollection 2021. Front Immunol. 2021. PMID: 34675942 Free PMC article. Review.
-
Correlation between the expression of hTERT gene and the clinicopathological characteristics of hepatocellular carcinoma.Oncol Lett. 2016 Jan;11(1):111-115. doi: 10.3892/ol.2015.3892. Epub 2015 Nov 9. Oncol Lett. 2016. PMID: 26870177 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials